Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Coronavirus vaccine components. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccination 119

Vaccination Vaccine Bacterium Protein 119

Scienmag

JUNE 2, 2022

An investigation into the evolution of Salmonella bacteria infecting Brazilian poultry shows that the introduction of a Salmonella vaccine, combined with increasing antibiotic usage by Brazilian farmers, has led to the rise of strains that are more antibiotic-resistant, but less likely to cause disease in humans.

Bacteria 78

Bacteria Vaccination Vaccine 78

Scienmag

NOVEMBER 9, 2020

— Similar to bacteria evolving resistance to antibiotics, viruses can evolve resistance to vaccines, and the evolution of SARS-CoV-2 could undermine the effectiveness of vaccines that are currently under development, according to a paper published November 9 in the open-access journal PLOS […]. UNIVERSITY PARK, Pa.

Vaccination 98

Vaccination Vaccine Bacteria Development 98

Scienmag

JULY 7, 2021

Researchers have produced vaccine-like immune responses to a dangerous bacterium by colonizing 26 healthy volunteers with a related, but harmless, commensal bacterial species.

Bacteria 75

Bacteria Bacterium Immune Response Vaccination 75

pharmaphorum

SEPTEMBER 28, 2021

Prospects for Valneva’s COVID-19 vaccine are up in the air, but another candidate partnered with Pfizer looks increasingly like it could fill the void of an effective shot for Lyme disease. billion contract to supply up to 100 million doses of its COVID-19 vaccine VLA2001.

Vaccination 105

Vaccination Vaccine Bacteria Protein 105

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 22, 2022

The Indian Institute of Science (IISc), Centre for BioSystems Science and Engineering, has designed a new method to deliver a vaccine candidate for tuberculosis (TB). The research involves using spherical vesicles secreted by bacteria coated on gold nanoparticles which can then be delivered to the immune cells.

Vaccination 100

Vaccination Vaccine Research Bacteria 100

Scienmag

JULY 8, 2021

A new vaccine technology combining capture of bacterial pathogens with effective immune-reprogramming biomaterials could be applied to a broad spectrum of infectious diseases Credit: Wyss Institute at Harvard University.

Vaccination 98

Vaccination Vaccine Bacteria Drugs 98

XTalks

JULY 28, 2021

Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Both next-gen shots offer enhanced protection against bacteria that can cause pneumonia, blood infections and meningitis.

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

XTalks

JULY 25, 2023

Emergent BioSolutions, a multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland, has achieved a significant milestone with the approval of its Cyfendus (Anthrax Vaccine Adsorbed, Adjuvanted) vaccine by the US Food and Drug Administration (FDA). anthracis , primarily affecting livestock and wild game.

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

Scienmag

OCTOBER 2, 2020

Credit: Virginia Tech Renowned tick immunobiologist Utpal Pal wants to ad apt the rabies vaccination platform to produce antibodies that can protect against Borrelia burgdorferi, the bacteria responsible for Lyme disease. The intention is to apply this work to other tick-borne diseases in the future.

Vaccination 88

Vaccination Vaccine Bacteria Development 88

Delveinsight

JULY 27, 2021

GlaxoSmithKline announced the US Food and Drug Administration approval for its vaccine, Shingrix (Zoster Vaccine Recombinant, Adjuvanted) under trials in 18+ adults who are vulnerable or at an increased risk to Shingles , which is already commercialized for patient group aged 50 and above.

Vaccination 96

Vaccination Vaccine Trials Manufacturing 96

Pfizer

FEBRUARY 16, 2023

who had been enrolled in the Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524) Phase 3 clinical study. The study is investigating the efficacy, safety and immunogenicity of an investigational Lyme disease vaccine candidate, VLA15. OspA is a surface protein expressed by the bacteria when present in a tick.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

XTalks

FEBRUARY 11, 2021

Amidst growing global shortages of COVID-19 vaccine supplies, inaugural (by way of authorizations/approvals) COVID-19 vaccine maker Pfizer is addressing the issue by working to cut the manufacturing time of its vaccine by almost half. Related: Pharma Rivals Step Up to Assist with COVID-19 Vaccine Production.

Manufacturing 52

Manufacturing Vaccination Vaccine DNA 52

pharmaphorum

MAY 31, 2022

billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer’s Prevnar franchise. The post GSK bolsters vaccines division with $3.3bn swoop on Affinivax appeared first on. GlaxoSmithKline has agreed a $3.3

Vaccination 52

Vaccination Vaccine Bacterium Sales 52

The Pharma Data

APRIL 26, 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

Vaccination 52

Vaccination Vaccine Bacteria Protein 52

The Pharma Data

MARCH 8, 2021

Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer Inc. It will compare the three-dose vaccination schedule (Month 0-2-6) with a two-dose schedule (Month 0-6). “We We are excited to be part of the Lyme disease vaccine development program with Valneva.

Vaccination 52

Vaccination Vaccine Bacteria Protein 52

The Pharma Data

OCTOBER 19, 2020

.–( BUSINESS WIRE )– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine. among adults 65 years of age or older.

Vaccination 52

Vaccination Vaccine Immune Response Containment 52

XTalks

APRIL 28, 2021

Stories about the development of COVID-19 vaccines have dominated the news for months, but a huge breakthrough in the prevention of another infectious disease has just been announced. Read the full articles here: Malaria Vaccine a Breakthrough Success with 77 Percent Efficacy. How Sugar May Impair Brain Development in Children.

Life Science 40

Life Science Vaccination Vaccine Development 40

Pharmaceutical Technology

MARCH 24, 2023

Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.

Vaccination 162

Vaccination Vaccine Clinical Trials Clinical Trials 162

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 11, 2024

Using viruses that infect bacteria to detect proteins sprouted by a notorious parasite, scientists have honed in on possible vaccine targets for schistosomiasis, a neglected tropical disease that currently affects an estimated 600 million people worldwide, causing 280,000 deaths per year.

Vaccination 240

Vaccination Vaccine Bacteria Protein 240

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3

Vaccination 195

Vaccination Vaccine Immune Response Bacteria 195

XTalks

JUNE 21, 2024

The US Food and Drug Administration (FDA) has green-lighted the first pneumonia vaccine specifically designed for adults 50 years of age and older. These numbers do not reflect the efficacies of the vaccines, which have not been compared head-to-head in any trial yet.

FDA Approval 108

FDA Approval Vaccination Vaccine Life Science 108

XTalks

AUGUST 17, 2022

August is National Immunization Awareness Month (NIAM), which is marked to help raise awareness about the importance of vaccines in the protection of public health. One of the themes of this year’s National Immunization Awareness Month is “vaccines work.” Vaccination Awareness from the FDA.

Vaccination 98

Vaccination Vaccine Bacteria Development 98

Pharma Times

DECEMBER 20, 2023

The Novo Nordisk Foundation has committed $260m to establish a new state-of-the-art research and vaccine development initiative to help combat deadly airborne infections. The initiative aims to create new or improved vaccines for deadly respiratory diseases, including tuberculosis (TB) and influenza. million deaths every year.

Vaccination 116

Vaccination Vaccine Immune Response Bacteria 116

Camargo

JULY 27, 2021

Gene therapy, which was in its infancy around 30 years ago, is now becoming a more prominent treatment method in many therapeutic areas, from personalized therapy to mass vaccinations against COVID-19.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. at Month 7). Juan Carlos Jaramillo M.D.,

Vaccination 52

Vaccination Vaccine Trials Bacteria 52

The Pharma Data

SEPTEMBER 30, 2021

As one among the leading global vaccines companies, we still bring options which help protect people’s health round the world,” said Michael Greenberg, MD, MPH, Medical Head, Sanofi Pasteur North America. “We 4,5 The CDC recommends a primary dose of the MenACWY vaccine at 11-12 years old and a second dose at 16 years old. In the U.S.,

Vaccination 52

Vaccination Vaccine Research Antibody 52

The Pharma Data

JUNE 18, 2021

First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, 1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and deaths in the U.S. Senior Vice President and Head of Vaccine Research & Development, Pfizer.

Vaccination 52

Vaccination Vaccine FDA Approval Containment 52

Scienmag

MAY 9, 2021

Researchers have successfully developed a new Strep A human challenge model, paving the way to test vaccines against the common deadly bacteria that causes sore throats, scarlet fever and skin sores.

Bacteria 49

Bacteria Vaccination Vaccine Research 49

XTalks

DECEMBER 12, 2023

The drug will have a boxed warning for increased risk of “life-threatening infections caused by encapsulated bacteria.” Given this, Fabhalta will be made available through a Risk Evaluation and Mitigation Strategy (REMS) program that requires vaccinations for encapsulated bacteria.

FDA Approval 95

FDA Approval Bacteria Trials Protein 95

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

XTalks

NOVEMBER 9, 2021

Perhaps popularized by the COVID-19 vaccines, RNA-based technologies now have the potential to become the next best pesticide to combat crop pests, like insects and fungal pathogens. Over the last year, researchers have been studying the effectiveness of RNA-based pesticides, and there are already a handful of sprays in the works.

RNA 98

RNA Gene Scientist Protein 98

Delveinsight

JULY 26, 2021

Often the bacteria develop antibiotic resistance to certain drugs, leaving it non-effective for the usage the second time in the case of recurrence of the infection that occurs in approximately 30-35% of the uUTI cases, therefore, leaving a serious dearth of the new antibiotics. coli bacteria called FimH.

Marketing 93

Marketing Bacteria Development Vaccine 93

Medical Xpress

DECEMBER 23, 2022

Formed in response to infection and vaccination, these microscopic training grounds allow B cells to perfect the antibodies they deploy against specific viruses and bacteria.

Bacteria 105

Bacteria Antibody Manufacturing Vaccine 105

Pharmaceutical Technology

MARCH 10, 2023

Pharmaceutical and biotechnology industries widely use freeze-drying systems to protect vaccines, antibodies, antibiotics such as penicillin, blood plasma, proteins, enzymes, hormones, viruses, and bacteria from heat and minimise their biological activity.

Manufacturing 147

Manufacturing Production Containment Antibody 147

Medical Xpress

MARCH 1, 2025

Often the perpetrators are viruses and bacteria you've conquered; others are undercover agents like vaccines given to trigger protective immune responses or even red herrings in the form of healthy tissue caught in immunological crossfire.

Immune Response 94

Immune Response Bacteria Vaccine Vaccination 94